Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 37 | 2024 | 4571 | 1.580 |
Why?
|
| Benzoxazines | 13 | 2021 | 321 | 1.180 |
Why?
|
| Anti-Retroviral Agents | 16 | 2024 | 1794 | 1.170 |
Why?
|
| HIV Infections | 48 | 2024 | 17575 | 1.150 |
Why?
|
| Ritonavir | 13 | 2021 | 330 | 0.850 |
Why?
|
| Lamivudine | 12 | 2022 | 367 | 0.680 |
Why?
|
| HIV-1 | 19 | 2023 | 6963 | 0.660 |
Why?
|
| Alkynes | 13 | 2021 | 327 | 0.580 |
Why?
|
| Cyclopropanes | 13 | 2021 | 437 | 0.560 |
Why?
|
| Infectious Disease Transmission, Vertical | 8 | 2023 | 1360 | 0.500 |
Why?
|
| HIV Protease Inhibitors | 6 | 2019 | 432 | 0.490 |
Why?
|
| Nevirapine | 5 | 2023 | 273 | 0.490 |
Why?
|
| Pregnancy Complications, Infectious | 9 | 2023 | 2185 | 0.480 |
Why?
|
| Hepatitis B | 4 | 2023 | 708 | 0.450 |
Why?
|
| Antiretroviral Therapy, Highly Active | 11 | 2023 | 1903 | 0.430 |
Why?
|
| Acquired Immunodeficiency Syndrome | 8 | 2020 | 2202 | 0.400 |
Why?
|
| Dideoxynucleosides | 9 | 2019 | 135 | 0.400 |
Why?
|
| Viral Load | 20 | 2021 | 3398 | 0.390 |
Why?
|
| Zidovudine | 5 | 2022 | 625 | 0.340 |
Why?
|
| RNA, Viral | 12 | 2024 | 2866 | 0.340 |
Why?
|
| Suicidal Ideation | 3 | 2021 | 1462 | 0.330 |
Why?
|
| DNA, Viral | 4 | 2024 | 2205 | 0.320 |
Why?
|
| Oligopeptides | 6 | 2014 | 1194 | 0.310 |
Why?
|
| Hepatitis B virus | 4 | 2023 | 530 | 0.310 |
Why?
|
| CD4 Lymphocyte Count | 11 | 2023 | 2596 | 0.290 |
Why?
|
| Bone Density | 6 | 2023 | 3559 | 0.290 |
Why?
|
| Deoxycytidine | 7 | 2014 | 888 | 0.280 |
Why?
|
| Suicide | 2 | 2017 | 1607 | 0.280 |
Why?
|
| Hepatitis B, Chronic | 2 | 2023 | 413 | 0.270 |
Why?
|
| Adenine | 8 | 2014 | 993 | 0.270 |
Why?
|
| Antiviral Agents | 4 | 2019 | 3064 | 0.250 |
Why?
|
| Herpesvirus 1, Cercopithecine | 1 | 2023 | 2 | 0.220 |
Why?
|
| Breast Feeding | 3 | 2022 | 1364 | 0.220 |
Why?
|
| Hepatitis C | 1 | 2013 | 1593 | 0.220 |
Why?
|
| Pneumocystis carinii | 1 | 2023 | 72 | 0.200 |
Why?
|
| Pyridines | 6 | 2014 | 2889 | 0.200 |
Why?
|
| Pyrimidinones | 4 | 2010 | 386 | 0.200 |
Why?
|
| Carbamates | 3 | 2015 | 192 | 0.190 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2023 | 242 | 0.190 |
Why?
|
| HIV | 6 | 2023 | 1596 | 0.180 |
Why?
|
| Drug Combinations | 9 | 2021 | 2079 | 0.180 |
Why?
|
| Milk, Human | 2 | 2023 | 489 | 0.180 |
Why?
|
| Postpartum Period | 4 | 2021 | 1197 | 0.170 |
Why?
|
| Hepatitis B e Antigens | 4 | 2023 | 135 | 0.170 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 962 | 0.150 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2017 | 61 | 0.140 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2020 | 622 | 0.140 |
Why?
|
| Infant | 14 | 2024 | 36510 | 0.140 |
Why?
|
| Adult | 44 | 2024 | 223640 | 0.130 |
Why?
|
| Sulfonamides | 3 | 2015 | 1980 | 0.130 |
Why?
|
| Female | 54 | 2024 | 397089 | 0.130 |
Why?
|
| Pregnancy | 13 | 2023 | 30200 | 0.120 |
Why?
|
| Plasma | 2 | 2015 | 585 | 0.120 |
Why?
|
| Pharmacogenetics | 2 | 2017 | 683 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2022 | 10377 | 0.120 |
Why?
|
| Cystatin C | 1 | 2015 | 272 | 0.110 |
Why?
|
| Drug Therapy, Combination | 9 | 2021 | 6318 | 0.110 |
Why?
|
| Male | 44 | 2024 | 364902 | 0.110 |
Why?
|
| Oxazines | 2 | 2005 | 357 | 0.110 |
Why?
|
| Humans | 61 | 2024 | 768393 | 0.100 |
Why?
|
| Drug Resistance, Viral | 3 | 2012 | 869 | 0.100 |
Why?
|
| Organic Anion Transporters | 1 | 2013 | 101 | 0.100 |
Why?
|
| Area Under Curve | 4 | 2021 | 1642 | 0.100 |
Why?
|
| Glucuronosyltransferase | 1 | 2012 | 136 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 1395 | 0.100 |
Why?
|
| Treatment Failure | 5 | 2017 | 2663 | 0.090 |
Why?
|
| Proteinuria | 1 | 2014 | 613 | 0.090 |
Why?
|
| Albuminuria | 1 | 2014 | 658 | 0.090 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2011 | 138 | 0.090 |
Why?
|
| Inflammation | 3 | 2015 | 10863 | 0.080 |
Why?
|
| Child Development | 1 | 2021 | 2334 | 0.080 |
Why?
|
| Research Design | 2 | 2022 | 6210 | 0.080 |
Why?
|
| Double-Blind Method | 8 | 2019 | 12456 | 0.080 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 1998 | 0.070 |
Why?
|
| Infant, Newborn | 7 | 2023 | 26411 | 0.070 |
Why?
|
| Patient Selection | 1 | 2020 | 4266 | 0.070 |
Why?
|
| Medication Adherence | 2 | 2017 | 2189 | 0.070 |
Why?
|
| Stavudine | 2 | 2009 | 85 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2022 | 5099 | 0.070 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2007 | 68 | 0.070 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2018 | 294 | 0.070 |
Why?
|
| Hepatitis B Vaccines | 2 | 2018 | 178 | 0.070 |
Why?
|
| Gestational Age | 3 | 2020 | 3615 | 0.060 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2005 | 109 | 0.060 |
Why?
|
| Absorptiometry, Photon | 3 | 2021 | 1752 | 0.060 |
Why?
|
| Suicide, Attempted | 1 | 2014 | 1409 | 0.060 |
Why?
|
| Drug Monitoring | 1 | 2011 | 964 | 0.060 |
Why?
|
| Middle Aged | 23 | 2019 | 223491 | 0.060 |
Why?
|
| Young Adult | 12 | 2024 | 60049 | 0.060 |
Why?
|
| Furans | 3 | 2015 | 201 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 246 | 0.060 |
Why?
|
| Alanine Transaminase | 2 | 2018 | 605 | 0.060 |
Why?
|
| Body Composition | 1 | 2013 | 2461 | 0.060 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 2742 | 0.050 |
Why?
|
| Cause of Death | 1 | 2014 | 3728 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2012 | 2593 | 0.050 |
Why?
|
| Zalcitabine | 1 | 2002 | 43 | 0.050 |
Why?
|
| Adolescent | 13 | 2024 | 89184 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2014 | 2906 | 0.050 |
Why?
|
| RNA | 2 | 2023 | 2726 | 0.050 |
Why?
|
| Didanosine | 1 | 2002 | 151 | 0.050 |
Why?
|
| Nutritional Support | 1 | 2024 | 178 | 0.050 |
Why?
|
| Body Weight | 1 | 2013 | 4629 | 0.050 |
Why?
|
| Cytokines | 1 | 2017 | 7445 | 0.050 |
Why?
|
| Viremia | 2 | 2021 | 725 | 0.050 |
Why?
|
| Receptors, CXCR4 | 1 | 2007 | 729 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2012 | 3230 | 0.050 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2006 | 664 | 0.050 |
Why?
|
| Fractures, Bone | 2 | 2011 | 2062 | 0.050 |
Why?
|
| Depression | 1 | 2021 | 8241 | 0.050 |
Why?
|
| Osteoporosis | 1 | 2011 | 1606 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2006 | 754 | 0.050 |
Why?
|
| Cerebrospinal Fluid | 1 | 2024 | 545 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 4357 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2013 | 10117 | 0.050 |
Why?
|
| Treatment Outcome | 8 | 2017 | 65379 | 0.040 |
Why?
|
| Administration, Oral | 3 | 2018 | 4039 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 3857 | 0.040 |
Why?
|
| Lumbar Vertebrae | 2 | 2023 | 1885 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 523 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2014 | 6430 | 0.040 |
Why?
|
| Uganda | 1 | 2024 | 1351 | 0.040 |
Why?
|
| Parturition | 1 | 2023 | 453 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 839 | 0.040 |
Why?
|
| Phosphates | 1 | 2022 | 765 | 0.040 |
Why?
|
| Infant Formula | 1 | 2020 | 195 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2023 | 577 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 751 | 0.040 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 12558 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2005 | 4250 | 0.040 |
Why?
|
| Mothers | 2 | 2020 | 2211 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 8051 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 39407 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 997 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2021 | 620 | 0.030 |
Why?
|
| Drug Interactions | 2 | 2015 | 1420 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2022 | 1595 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2024 | 42650 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 12092 | 0.030 |
Why?
|
| Thailand | 1 | 2016 | 288 | 0.030 |
Why?
|
| Half-Life | 2 | 2007 | 650 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 1197 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2014 | 363 | 0.030 |
Why?
|
| Genotype | 3 | 2017 | 13042 | 0.030 |
Why?
|
| Health Resources | 1 | 2020 | 950 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2016 | 855 | 0.030 |
Why?
|
| Pelvic Bones | 1 | 2015 | 274 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2013 | 380 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2020 | 54920 | 0.030 |
Why?
|
| Jaundice | 1 | 2012 | 95 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 1673 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2022 | 2708 | 0.020 |
Why?
|
| Consensus | 1 | 2022 | 3212 | 0.020 |
Why?
|
| Cohort Studies | 4 | 2021 | 41795 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 2961 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 640 | 0.020 |
Why?
|
| Bilirubin | 1 | 2012 | 438 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2017 | 3617 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 541 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 417 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2011 | 246 | 0.020 |
Why?
|
| DNA | 1 | 2023 | 7211 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 2009 | 134 | 0.020 |
Why?
|
| Child | 3 | 2023 | 80891 | 0.020 |
Why?
|
| Antidepressive Agents | 1 | 2021 | 2913 | 0.020 |
Why?
|
| Calcium | 1 | 2022 | 5794 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 1742 | 0.020 |
Why?
|
| United States | 3 | 2024 | 73150 | 0.020 |
Why?
|
| Kidney | 1 | 2023 | 7064 | 0.020 |
Why?
|
| Butylamines | 1 | 2007 | 9 | 0.020 |
Why?
|
| Aminoquinolines | 1 | 2007 | 105 | 0.020 |
Why?
|
| Prevalence | 1 | 2024 | 15872 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 10776 | 0.020 |
Why?
|
| Self Report | 1 | 2017 | 3766 | 0.020 |
Why?
|
| Disease Progression | 1 | 2002 | 13646 | 0.020 |
Why?
|
| Time Factors | 3 | 2014 | 40272 | 0.010 |
Why?
|
| Linear Models | 1 | 2014 | 5878 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2022 | 22296 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2014 | 2660 | 0.010 |
Why?
|
| Incidence | 1 | 2021 | 21544 | 0.010 |
Why?
|
| Models, Biological | 1 | 2019 | 9493 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2004 | 423 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 4859 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 30022 | 0.010 |
Why?
|
| Benzimidazoles | 1 | 2007 | 864 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2009 | 6241 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6541 | 0.010 |
Why?
|
| Fasting | 1 | 2007 | 1610 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 1727 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2011 | 2693 | 0.010 |
Why?
|
| Sex Factors | 1 | 2013 | 10654 | 0.010 |
Why?
|
| Headache | 1 | 2007 | 1262 | 0.010 |
Why?
|
| Leukocytes | 1 | 2007 | 2030 | 0.010 |
Why?
|
| Aged | 3 | 2021 | 171562 | 0.010 |
Why?
|
| Age Factors | 1 | 2015 | 18471 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2005 | 1277 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 16028 | 0.010 |
Why?
|
| Risk Factors | 2 | 2017 | 74962 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2012 | 6606 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2006 | 3164 | 0.010 |
Why?
|
| Logistic Models | 1 | 2011 | 13323 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 4411 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2006 | 4646 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20765 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 59686 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2009 | 81801 | 0.000 |
Why?
|
Concepts
(206)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(19)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_